Core Insights - The Chinese pharmaceutical industry is transitioning from "generic following" to "innovation leading," with 704 original innovative drugs expected from Chinese companies in 2024, ranking first globally [2][3] - Zhang Yingjun, Chairman of Dongyangguang Pharmaceutical, emphasizes that the industry is entering a "golden decade" driven by innovation and internationalization, supported by continuous policy empowerment [2][3] Industry Overview - The Chinese pharmaceutical sector is experiencing a strategic opportunity period centered on innovation and internationalization, particularly after the implementation of the "7.22" clinical data verification policy [2] - The full-chain support system for the pharmaceutical industry is being established, with innovative drugs consistently included in government work reports [2] Company Strategy - Dongyangguang Pharmaceutical is committed to source innovation, with a research pipeline covering various technologies such as small molecules, antibodies, small nucleic acids, ADCs, and cell therapies [2][3] - The company's research strategy has shifted from "Me-too" and "Fast-follow" to pursuing "BIC (Best in Class)" and "FIC (First in Class)" [2] Research and Development - Dongyangguang Pharmaceutical has nearly 50 research pipelines, with over 10 in registration or key clinical stages, showcasing potential products like the functional cure for hepatitis B and new drugs for IPF [3] - The company has developed six AI models to enhance drug discovery capabilities, with the first AI-driven small molecule drug entering clinical trials, showing promising initial data [3] Internationalization Efforts - The company's international strategy includes a diversified approach, such as "License-out" agreements and promoting self-developed products in Europe and the U.S., with the expectation of launching insulin glargine in the U.S. by Q1 2026 [4] - Dongyangguang Pharmaceutical has established a global sales network, with over 60 overseas formulations approved and leading market share in certain products [4] Future Outlook - The company aims to become a leading comprehensive pharmaceutical company through innovation, internationalization, and sustainability, targeting over 20 billion yuan in revenue and 5 billion yuan in profit within five years [4] - The progression of Chinese pharmaceutical companies is fundamentally about the global recognition and validation of innovative value, with Dongyangguang Pharmaceutical actively participating in this historical process [4]
以“创新+国际化”双引擎 开启中国药企进阶新篇章